DAFTAR PUSTAKA

1. Welliver C, Helo S, McVary KT. Technique considerations and complication

management in transurethral resection of the prostate and photoselective
vaporization of the prostate. Transl Androl Urol. 2017;6(4):695–703.
2. Gravas S, et al. Guidelines on the Management of Male Lower Urinary Tract
Symptoms Benign Prostatic Obstruction ( BPO ). Eur Assoc Urol.
2012;64:118–40.
3. Fitzpatrick JM, Desgrandchamps F, Adjali K, et al. Management of acute
urinary retention: a worldwide survey of 6074 men with benign prostatic
hyperplasia. BJU Int. 2012;109(1):88-95.a
4. Anutrakulchai S. Residual LUTS after Transurethral Resection of Prostate
( TURP ): The Urodynamic Studies in Chiangmai University. Thai J Surg.
2005;26:82–7.
5. Zhang Z, Cao Z, Xu C, et al. Solifenacin is able to improve the irritative
symptoms after transurethral resection of bladder tumors. Urology
2014;84:117–121.
6. Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive
bladder. Int Urogynecol J. 2012;23(8):975–82
7. Anger JT, Goldman HB, Luo X, Carlsson MO, Chapman D, Zou KH, et al.
Patterns of medical management of overactive bladder (OAB) and benign
prostatic hyperplasia (BPH) in the United States. Neurourol Urodyn.
2018;37(1):213–22.
8. Agarwal A, Dhiraaj S, Singhal V, et al. Comparison of efficacy of
oxybutynin and tolterodine for prevention of catheter related bladder
discomfort: a prospective, randomized, placebo-controlled, double-blind
study. Br J Anaesth, 2006,96(3):377-380
9. Yadav G, Prashanth M, Singh RB, Jain G, Singh Y, Meena RK. Incidence
and severity of catheter related bladder discomfort by using different
inhalational anesthetic agents and comparing it with propofol. Anaesth Pain
& Intensive Care 2015; 19(4):452-456

Fakultas Kedokteran Universitas Andalas 43

10. Hu B, Li C, Pan M, Zhong M, Cao Y, Zhang N, et al. Strategies for the
preventionof catheter-related bladder discomfort. Medicine(Baltimore). 2016;
95(37) : e4859.
11. Bai Y, Wang X, Li X, Pu C, Yuan H, Tang Y, et al. Management of
Catheter-Related Bladder Discomfort in Patients Who Underwent Elective
Surgery. J Endourol. 2015;29(6):640–9.
12. Andersson KE. Detrusor myocyte activity and afferent signaling. Neurourol
Urodyn 2010;29:97–106
13. Srivastava VK, Agrawal S, Kadiyala VN, Ahmed M, Sharma S, Kumar R.
The efficacy of pregabalin for prevention of catheter-related bladder
discomfort: a prospective, randomized, placebo-controlled double-blind
study. J Anesth. 2015;29(2):212–6.
14. Li J yi, Liao R. Prevention of catheter-related bladder discomfort - pudendal
nerve block with ropivacaine versus intravenous tramadol: Study protocol for
a randomized controlled trial. Trials. Trials; 2016;17(1):1–6.
15. Bai Y, Wang X, Li X, et al. Management of catheter-related bladder
discomfort in patients who underwent elective surgery. J
Endourol. 2015;29:640–649.
16. Maro S, Zarattin D, Baron T, Bourez S, de la Taille A, Salomon L.
Catheter-related bladder discomfort after urological surgery: Importance of
the type of surgery and efficiency of treatment by clonazepam. Prog Urol
2014;24: 628–633.
17. Binhas M, Motamed C, Hawajri N, Yiou R, Marty J. Facteurs prédictifs
d’inconfort de sonde vésicale en salle de réveil. Ann Fr Anesth Reanim.
Elsevier Masson SAS; 2011;30(2):122–5.
18. Li C, Liu Z, Yang F. Predictors of catheter-related bladder discomfort after
urological surgery. J Huazhong Univ Sci Technol - Med Sci.
2014;34(4):559–62.
19. Manley K V., Hubbard R, Swallow D, Finch W, Wood SJ, Biers SM. Risk
factors for development of primary bladder squamous cell carcinoma. Ann R
Coll Surg Engl. 2017;99(2):155–60.

Fakultas Kedokteran Universitas Andalas 44

20. Birder L, Andersson K-E. Urothelial Signaling. Physiological Reviews.
2013;93(2):653-680.
21. Roehrborn CG. BPH progression: concept and key learning from MTOPS,
ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101(suppl 3):17-21.
22. Oelke M, Hofner K, Jonas U, et al. Benign prostatic hyperplasia:
terminology and assessment. Dtsch Arztebl 2007;104(33): A 2261-7.
23. Chapple C, Abrams P. Male lower urinary tract symptoms (LUTS) an
international consultation on male LUTS Fukuoka, Japan, September
30-October 4, 2012. Montreal: Societe Internationale d’Urologie.
2013.hal.42-3.
24. Briolat GM. Benign prostatic hyperplasia. Nurse Pract Urol. Macmillan
Publishers Limited; 2016;2:117–26.
25. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project:
benign prostatic hyperplasia. J Urol 2005, 173:1256–61.
26. Data pasien BPH RSCM tahun 1994-2013
27. Data pasien BPH RSHS tahun 2012-2016. Diakses Februari 2017 (Belum
dipublikasi)
28. Parsons JK: Benign Prostatic Hyperplasia and Male Lower Urinary Tract
Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep.
2010;5:212–18.
29. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and
lower urinary tract symptoms: New approaches to old problems. J
Urol. 2007;178:395–401.
30. Kaplan SA, O’Neill E, Lowe R, Hanson M, Meehan AG. Prevalence of low
testosterone in aging men with benign prostatic hyperplasia: Data from the
Proscar Long-term Efficacy and Safety Study (PLESS) Aging
Male. 2013;16:48–51
31. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ,
et al. Serum steroid and sex hormone-binding globulin concentrations and
the risk of incident benign prostatic hyperplasia: Results from the prostate
cancer prevention trial. Am J Epidemiol. 2008;168:1416–24.

Fakultas Kedokteran Universitas Andalas 45

32. Nandeesha H. Benign Prostatic Hyperplasia: dietary and metabolic risk
factors. Int Urol Nephrol (2008) 40: 649-56.
33. Parsons JK, Kashefi C. Physical Activity , Benign Prostatic Hyperplasia ,
and Lower Urinary Tract Symptoms. Eur Urol. 2008;53(6):1228–35.
34. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF,
et al. Dietary patterns, supplement use, and the risk of symptomatic benign
prostatic hyperplasia: results from the prostate cancer prevention trial. Am J
Epidemiol. 2008;167(8):925–34.
35. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum
C-reactive protein concentration and lower urinary tract symptoms in older
men in the Third National Health and Nutrition Examination Survey
(NHANES III) Prostate. 2005;62:27–33.
36. Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC,
Rittmaster RS. The relationship between prostate inflammation and lower
urinary tract symptoms: Examination of baseline data from the REDUCE
trial. Eur Urol. 2008;54:1379–84.
37. Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing
normal reference ranges for prostate volume change with age in the
population-based Krimpen-study: Prediction of future prostate volume in
individual men. Prostate. 2007;67:1816–24.
38. Soni A, Bansal A, Mishra AK, Batra J, Singh LC, Chakraborty A, et al.
Association of androgen receptor, prostate-specific antigen, and CYP19 gene
polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a
north Indian population. Genet Test Mol Biomarkers. 2012;16:835–40.
39. Ganpule AP, Desai MR, Desai MM, Wani KD, Bapat SD. Natural history of
lower urinary tract symptoms: Preliminary report from a community-based
Indian study. BJU Int. 2004;94:332–4.
40. Purnomo B. Basuki. Dasar-dasar Urologi. Ed 3. Jakarta: Penerbit Buku CV
Sagung Seto, 2011; hlmn 125-144.
41. Foster, CS. Pathology of benign prostatic hyperplasia. Prostate Suppl. 2000;9:
4–14 .

Fakultas Kedokteran Universitas Andalas 46

42. Niu, Y. et al. Proliferation and differentiation of prostatic stromal cells. BJU
Int. 2001;87, 386–393.
43. Carson, C. 3rd & Rittmaster, R. The role of dihydrotestosterone in benign
prostatic hyperplasia. Urology. 2003;61:2–7.
44. Chughtai, B., Lee, R., Te, A. & Kaplan, S. Inflammation and benign prostatic
hyperplasia: clinical implications. Curr Urol Rep. 2011; 12, 274–277.
45. Robert, G. et al. Inflammation in benign prostatic hyperplasia: a 282 patients’
immunohistochemical analysis. Prostate. 2009; 69: 1774–1780.
46. Wang, W., Bergh, A. & Damber, J. E. Chronic inflammation in benign
prostate hyperplasia is associated with focal upregulation of
cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.
Prostate. 2004:61: 60–72.
47. Unnikrishnan R, Almassi N, Fareed K. Benign prostatic hyperplasia:
Evaluation and medical management in primary care. Cleve Clin J Med.
2017; 84(1):53–64.
48. Roehrborn, C. G. & Schwinn, D. A. α1-Adrenergic receptors and their
inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
J. Urol. 2004; 171: 1029–1035.
49. Andersson, K.-E. α-Adrenoceptors and benign prostatic hyperplasia: basic
principles for treatment with α-adrenoceptor antagonists. World J. Urol. 2002;
19: 390–396.
50. Siroky, M. B. The aging bladder. Rev. Urol. 2004; 6: S3–S7.
51. Briolat GM. Benign prostatic hyperplasia. Nurse Pract Urol. 2016;2:117–26.
52. Levin, R. M. et al. Obstructive response of human bladder to BPH versus
rabbit bladder response to partial outlet obstruction: a direct comparison.
Neurourol. Urodynam. 2000; 19: 609–629.
53. Gerber GS, Brendler CB. Evaluation of the Urologic Patient:History,
Physical Examination, and Urinalysis. In: Campbell-Walsh Urology. 10th
Edition. Philadelphia: Elsevier Saunders 2012; p. 71-80.
54. McVary KT, et al. Update on AUA guideline on the management of benign
prostatic hyperplasia. J Urol. 2011;185(5):1793-803.

Fakultas Kedokteran Universitas Andalas 47

55. Gravas S, et al. Guidelines on the Management of Male Lower Urinary Tract
Symptoms Benign Prostatic Obstruction ( BPO ). Eur Assoc Urol.
2012;64:118–40.
56. D'Silva KA, Dahm P, Wong CL. Does this man with lower urinary tract
symptoms have bladder outlet obstruction?: The Rational Clinical
Examination: a systematic review. JAMA. 2014;312(5):535-42.
57. Presti JC . Neoplasm of the prostate gland Neoplasma in prostate gland. in
McAninchh JW, Lue TF (eds) . Smith and Tanagho’s General Urology . 16th
ed . New York : Lange Medical Book/McGraw-Hill; 2003. p. 267-276
58. Unnikrishnan R, Almassi N, Fareed K. Benign prostatic hyperplasia:
Evaluation and medical management in primary care. Cleve Clin J Med.
2017;84(1):53–64.
59. McNicholas TA, Kirby RS, Lepor H. and non-surgical management of
benign prostatic hyperplasia. Campbell's urology. 10th ed. Philadelphia: WB
Saunders Co., 2012. 2612 - 2640.
60. Welliver C, Helo S, McVary KT. Technique considerations and complication
management in transurethral resection of the prostate and photoselective
vaporization of the prostate. Transl Androl Urol. 2017;6(4):695–703.
61. Macey MR, Raynor MC. Medical and Surgical Treatment Modalities for
Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign
Prostatic Hyperplasia : A Review. Semin Intervent Radiol.
2016;1(212):220–1.
62. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural
history of lower urinary tract dysfunction in men: Minimum 10-year
urodynamic followup of transurethral resection of prostate for bladder outlet
obstruction. J Urol 2005;174:1887-91.
63. Chughtai B, Simma-Chiang V, Kaplan A S. Evaluation and Management of
Post-Transurethral Resection of the Prostate Lower Urinary Tract
Symptoms.Department of Urology, Weil Cornell Medical College, New
York. Curr Urol Rep (2014) 15;434.

Fakultas Kedokteran Universitas Andalas 48

64. Burke, N., et al. Systematic review and meta-analysis of transurethral
resection of the prostate versus minimally invasive procedures for the
treatment of benign prostatic obstruction. Urology. 2010. 75: 1015.
65. Golam Robbani A.B.M., Salam M. A., Anowarul Islam A. K. M.
Transurethral Resection (TURP) Versus Transurethral Incision (TUIP) of the
Prostate for Small Sized Benign Prostatic Hyperplasia: A Prospective
Randomized Study. TAJ. 2006; 19(2): 50-56.
66. Christidis D, Mcgrath S, Perera M, Manning T, Bolton D, Lawrentschuk N.
Minimally invasive surgical therapies for benign prostatic hypertrophy : The
rise in minimally invasive surgical therapies. Prostate Int. Elsevier Ltd;
2017;5(2):41–6.
67. Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or
tamsulosin similarly improved lower urinary tract symptoms suggestive of
benign prostatic hyperplasia in an international, randomised, parallel,
placebo-controlled clinical trial. Eur Urol. 2012;61(5):917-25.
68. Speakman MJ, Cheng X. Management of the complications of
BPH/BOO. Indian J Urol. 2014;30(2):208-13.
69. Gravas S, T Bach, Bachmann A, et al. EAU Guidelines on the Management
of NonNeurogenic Male Lower Urinary Tract Symptoms (LUTS), incl.
Benign Prostatic Obstruction (BPO). European Association of Urology 2016.
70. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence
estimates of lower urinary tract symptoms, overactive bladder, urinary
incontinence and bladder outlet obstruction. BJU Int 2011; 108: 1132–8
71. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary
incontinence, overactive bladder, and other lower urinary tract symptoms in
five countries: results of the EPIC study. Eur Urol 2006; 50: 1306–15.
72. Tirtayasa PMW, Rahardjo HE. A survey on the management of overactive
bladder by Indonesian urologists. Med J Indones. 2015;24(2):91–6.
73. Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive
bladder. Int Urogynecol J. 2012;23(8):975–82.
74. Brading A. Overactive bladder: why it occurs. Women’s Health Med. 2005;
2: 20–3.

Fakultas Kedokteran Universitas Andalas 49

75. Brading AF, Symes S. Ischemia as an etiological factor in bladder instability:
implications for therapy. Adv Exp Med Biol. 2003; 539: 255–69.
76. Sui G, Fry CH, Malone-Lee J, Wu C. Aberrant Ca2+ oscillations in smooth
muscle cells from overactive human bladders. Cell Calcium. 2009; 45:
456–64.
77. Kessler TM, Burkhard FC, Z’Brun S et al. Effect of thalamic deep brain
stimulation on lower urinary tract function. Eur Urol. 2008; 53: 607–12.
78. Hougaard C, Fraser MO, Chien C et al. A positive modulator of K Ca 2 and
K Ca 3 channels, 4,5-dichloro-1,3-diethyl1,3-dihydro-benzoimidazol-2-one
(NS4591), inhibits bladder afferent firing in vitro and bladder overactivity in
vivo. J Pharmacol Exp Ther. 2009; 328: 28–39.
79. Shioyama R, Aoki Y, Ito H et al. Long-lasting breaches in the bladder
epithelium lead to storage dysfunction with increase in bladder PGE2 levels
in the rat. Am J Physiol Regul Integr Comp Physiol 2008; 295: R714–8.
80. Housami F, Abrams P. Persistent detrusor overactivity after transurethral
resection of the prostate. Curr Urol Rep 2008; 9: 284–90.
81. Alberti KG, Zimmet P, Shaw J et al. The metabolic syndrome—a new
worldwide definition. Lancet. 2005; 366(9491): 1059–62.
82. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between
markers of the metabolic syndrome and lower urinary tract symptoms in the
Third National Health and Nutrition Examination Survey (NHANES III). Int
J Obes (Lond). 2005; 29: 310–6.
83. Lee WC. The impact of diabetes on the lower urinary tract dysfunction.
JTUA 2009; 20: 155–61.
84. Liu RT, Chung MS, Lee WC et al. Prevalence of Overactive Bladder (OAB)
and associated risk factors in 1,359 patients with type 2 diabetes. Urology
2011; 78: 1040–5.
85. Tong YC, Cheng JT. Alterations of M2,3-muscarinic receptor protein and
mRNA expression in the bladder of the fructose fed obese rat. J Urol 2007;
178: 1537–42

Fakultas Kedokteran Universitas Andalas 50

86. Lee WC, Chien CT, Yu HJ, Lee SW. Bladder dysfunction in rats with
metabolic syndrome induced by long-term fructose feeding. J Urol. 2008;
179: 2470–6.
87. Lee WC, Chuang YC, Chiang PH, Chien CT, Yu HJ, Wu CC.
Pathophysiological studies of overactive bladder and bladder motor
dysfunction in a rat model of metabolic syndrome. J Urol. 2011; 186:
318–25.
88. Yoshida M, Masunaga K, Nagata T, Satoji Y, Shiomi M. The effects of
chronic hyperlipidemia on bladder function in myocardial infarction-prone
Watanabe heritable hyperlipidemic (WHHLMI) rabbits. Neurourol Urodyn.
2010; 29: 1350–4.
89. Azadzoi KM, Shinde VM, Tarcan T et al. Increased leukotriene and
prostaglandin release, and overactivity in the chronically ischemic bladder. J
Urol 2003; 169: 1885–91.
90. Azadzoi KM, Radisavljevic ZM, Golabek T et al. Oxidative modification of
mitochondrial integrity and nerve fiber density in the ischemic overactive
bladder. J Urol 2010; 183: 362–9.
91. Yang SSD, Wang CC, Hsieh JH, Chen YT. α1-Adrenergic blockers in young
men with primary bladder neck obstruction. J Urol 2002; 168: 571–4.
92. Kupelian V, McVary KT, Barry MJ et al. Association of C-reactive protein
and lower urinary tract symptoms in men and women: results from Boston
area community health survey. Urology 2009; 73: 950–7.
93. Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P. Urine and serum
C-reactive protein levels as potential biomarkers of lower urinary tract
symptoms. Urol Sci 2010; 21: 132–6.
94. Lee T, Andersson KE, Streng T, Hedlund P. Simultaneous registration of
intraabdominal and intravesical pressures during cystometry in conscious
rats—effects of bladder outlet obstruction and intravesical PGE2. Neurourol
Urodyn 2008; 27: 88–95.
95. Homma Y, Kakizaki H, Yamaguchi O, Yamanishi T, Nishizawa O,
Yokoyama O, et al. Assessment of overactive bladder symptoms:

Fakultas Kedokteran Universitas Andalas 51

 comparison of 3-day bladder diary and the overactive bladder symptoms
score. Urology. 2011;77:60–4.
96. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et
al. Diagnosis and Treatment of Overactive Bladder ( Non-Neurogenic ) in
Adults : AUA / SUFU Guideline. JURO. Elsevier Inc.;
2012;188(6):2455–63.
97. Thuroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ,
Hampel C, Neisius A, Schröder A, Tubaro A: EAU Guidelines on Urinary
Incontinence. Actas Urol Esp. 2011;35:373–388.
98. Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki
H, Obara K, Gotoh M, Igawa Y, Seki N, Yoshida M: Clinical guidelines for
overactive bladder. Int J Urol 2009;16:126–142.
99. Hashim H, Abrams P: How should patients with an overactive bladder
manipulate their fluid intake? BJU Int 2008;102:62–66.
100. Lohsiriwat S, Hirunsai M, Chaiyaprasithi B: Effect of caffeine on bladder
function in patients with overactive bladder symptoms. Urol Ann
2011;3:14–18.
101. Kurita N, Yamazaki S, Fukumori N, et al. Overactive bladder symptom
severity is associated with falls in community-dwelling adults: LOHAS study.
BMJ Open. 2013;3(5).
102. Lai H, Gardner V, Vetter J, Andriole GL. Correlation between psychological
stress levels and the severity of overactive bladder symptoms. BioMed Cent
Urol. 2015;1–7.
103. Ramakrishnan K, Mold J. Urinary Catheters : A Review. Internet J Fam Pract.
2012;3(2):1–12.
104. Nazarko L. Catheter care in the community. Nurse Stand. 2008;14:46–51.
105. Bai Y, Wang X, Li X, et al. Management of Catheter-Related Bladder
Discomfort in Patients Who Underwent Elective Surgery. J Endourol.
2015;29(6):640-9.
106. Soper, D.S. (2018). A-priori Sample Size Calculator for Hierarchical
Multiple Regression.

Fakultas Kedokteran Universitas Andalas 52

107. Cohen, J, Cohen, P, West, S.G, and Aiken, L.S. (2003). Applied Multiple
Regression/Correlation Analysis for the Behavioral Sciences (3rd edition).
Mahwah, NJ: Lawrence Earlbaum Associates.
108. Sumardi R, Mochtar CA, Santoso BI. Test-retest Reliability of the
Indonesian Version of the Overactive Bladder Symptom Score ( OABSS )
and Its Correlation with Standard Assessment Tools. Acta Medica Indones
Indones J Intern Med. 2012;44(3):214–21.
109. Liu TT, Thomas S, Mclean DT, et al. Prostate enlargement and altered
urinary function are part of the aging process. Aging (Albany NY).
2019;11(9):2653–2669.
110. Jung JH, Reddy B, McCutcheon KA, et al. Prostatic urethral lift for the
treatment of lower urinary tract symptoms in men with benign prostatic
hyperplasia. Cochrane Database Syst Rev. John Wiley & Sons, Ltd;
2019 ;(5).
111. Mayer, E. K., Kroeze, S. G., Chopra, S., Bottle, A., & Patel, A. (2012).
Examining the ‘gold standard’: A comparative critical analysis of three
consecutive decades of monopolar transurethral resection of the prostate
(TURP) outcomes. BJU International, 110(11), 1595—1601.
112. Kusljic S, Aneja J, Manias E. Incidence of complications in men undergoing
transurethral resection of the prostate. Collegian. Australian College of
Nursing Ltd; 2017;24(1):3–9.
113. Lee CL, Kuo HC. Pathophysiology of benign prostate enlargement and lower
urinary tract symptoms: Current concepts. Ci Ji Yi Xue Za Zhi.
2017;29(2):79–83.
114. Shah J. Catheterisation. Ann R Coll Surg Engl. 2012;94(1):5–7.
115. Dougherty JM, Aeddula NR. Male Urinary Retention. [Updated 2019 Jun
30]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2019 Jan.
Available from:https://www.ncbi.nlm.nih.gov/books/NBK538499/
116. Akhavizadegan H. A Novel Technique for Post-Prostatectomy Catheter
Traction. Nephrourol Mon. 2016;8(4):e37394.

Fakultas Kedokteran Universitas Andalas 53

117. Abdelrahman M, Davis NF, McMahon BP, et al. A comparative assessment
of irrigation and drainage characteristics for commercially available urethral
catheters. Cent European J Urol. 2017;70(4):382–387.
118. Agbugui JO, Obarisiagbon EO, Osaigbovo II. Bacteriology of Urine
Specimens Obtained from Men with Symptomatic Benign Prostatic
Hyperplasia. Niger J Surg. 2016;22(2):65–69.
119. Pourmand G, Abedi AR, Karami AA, Khashayar P, Mehrsai AR. Urinary
infection before and after prostatectomy. Saudi J Kidney Dis
Transpl. 2010;21:290–4.
120. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic
hyperplasia: Clinical connections, emerging etiological paradigms and future
directions. J Urol. 2013;189:S102–6.
121 Khoubehi B, Watkin NA, Mee AD, Ogden CW. Morbidity and the impact on
redaily activities associated with catheter drainage after acute urinary
retention. BJU Int. 2000;85:1033–1036
122. Ugare UG, Bassey IA, Udosen EJ, Essiet A, Bassey OO. Management of
lower urinary retention in a limited resource setting. Ethiop J Health Sci.
2014;24(4):329–336.
123. Desgradchamps F, Dela Taille A, Doublet JD. The management of acute
urinary retention in France; a cross sectional survey in 2,618 men with
benign prostatic hyperplasia. BJU (int) 2006;97:727–733.
124. Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S. Correlation
between improvements in Overactive Bladder Symptom Score and
health-related quality of life questionnaires in overactive bladder patients
treated with an antimuscarinic drug. Neurourol Urodyn. 2011;30(7):1309-
1314.
125. De Nunzio C, Franco G, Rocchegiani A, et al. The evolution of detrusor
overactivity after watchful waiting, medical therapy and surgery in patients
with bladder outlet obstruction. J Urol 2003;169:535–9
126. Gacci M, Sebastianelli A, Spatafora P, et al. Best practice in the management
of storage symptoms in male lower urinary tract symptoms: a review of the
evidence base. Ther Adv Urol. 2017;10(2):79–92. Published 2017 Dec 7.

Fakultas Kedokteran Universitas Andalas 54

127. Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive Bladder
Syndrome: Evaluation and Management. Curr Urol. 2018;11(3):117–125.
128. Wan Q, Xiong G, Liu G, Shupe TD, Wei G, Zhang D, et al. Urothelium with
barrier function differentiated from human urine-derived stem cells for
potential use in urinary tract reconstruction. Stem Cell Res Ther. Stem Cell
Research & Therapy; 2018;9(1):304.
129. Birder L, WC de G. Mechanism of Disease: involvement of the urothelium in
bladder dysfunction. Nat Clin Pr Urol. 2011;4(1):46–54.
130. Fry CH, Vahabi B. The Role of the Mucosa in Normal and Abnormal
Bladder Function. Basic Clin Pharmacol Toxicol. 2016;119 Suppl 3(Suppl
3):57–62.
131. Merrill L, Gonzalez EJ, Girard BM, Vizzard MA. System in the Bladder.
2017;13(4):193–204.

Fakultas Kedokteran Universitas Andalas 55